Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408152 | 1.00 | NR3C1 (0.39) | NR3C1EPAS1VEGFAFFAR1MEN1 | |
| SCHEMBL23148790 | 0.86 | SLC22A12 (0.36) | EPAS1VEGFAMEN1TTRALB | |
| SCHEMBL10164859 | 0.83 | SLC22A12 (0.43) | SLC22A12AR | |
| SCHEMBL1963234 | 0.82 | NR3C1 (0.42) | NR3C1FFAR1MEN1TTRALB | |
| SCHEMBL16951654 | 0.82 | ALDH1A1 (0.31) | — | |
| SCHEMBL2448493 | 0.80 | USP30 (0.41) | SLC22A12CYP11B1CYP11B2AR | |
| SCHEMBL12619038 | 0.79 | NR3C1 (0.45) | NR3C1EPAS1FFAR1 | |
| SCHEMBL16955678 | 0.79 | SLC22A12 (0.36) | SLC22A12CYP11B1CYP11B2AR | |
| SCHEMBL16177839 | 0.79 | CA12 (0.38) | SLC22A12CYP11B1CYP11B2AR | |
| SCHEMBL14150477 | 0.79 | KDM4E (0.39) | SLC22A12AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4213832-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3976608-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3969439-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-03-23 | — | — | EP | disclosed |
| CN-114127049-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114127062-A | Thiadiazolyl derivatives as inhibitors of DNA polymerase Theta | 伊迪亚生物科学有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | NR3C1 458/4885EPAS1 1585/4885VEGFA 3167/4885 |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | NR3C1 2049/4885EPAS1 183/4885VEGFA 4797/4885 |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | POLQ, POLK, POLA1 | NR3C1 2717/4885EPAS1 1165/4885VEGFA 3689/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | NR3C1 647/4885EPAS1 427/4885VEGFA 4128/4885 |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | NR3C1 4721/4885EPAS1 1139/4885VEGFA 4684/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | NR3C1 3639/4885EPAS1 2789/4885VEGFA 3189/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | NR3C1 2049/4885EPAS1 183/4885VEGFA 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.